Immunotherapy | Topics

Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.

Acceptable efficacy and safety were elicited in patients with advanced solid tumors and high tumor mutational burden detectable in both blood and tissue samples with nivolumab/ipilimumab therapy.

Shilpa Gupta, MD, and Jason R. Brown, MD, PhD, discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Investigators reported that the development of cutaneous immune-related adverse effects has a strong association with response in survival among patients with cancer treated with immunotherapy.

Retrospective data suggest survival outcomes were positive and safety was reasonable for patients with cancer aged 80 years or older who received immune checkpoint inhibitors.

Patients with advanced cancers who were ineligible for trials were more likely to receive frontline immune checkpoint inhibitor monotherapy than patients with the same advanced cancers who were eligible for trials.

Roy S. Herbst, MD, PhD, shares insight on approaching clinical decision-making for the length of immunotherapy treatment and drug holidays for patients with NSCLC.

An expert in thoracic oncology provides an overview of ctDNA and discusses what ctDNA testing results can indicate about a patient’s likelihood of responding to immunotherapy in NSCLC.

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.